• Explore /
  • Poster
  • / A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.

A phase 1, open-label, dose escalation study of enoblituzumab (MGA271) in pediatric patients with B7-H3-expressing relapsed or refractory solid tumors.

Abstract Poster

Authors

null

Kenneth Desantes

University of Wisconsin, Madison, WI

Kenneth Desantes , John M. Maris , Kimberly McDowell , Crystal Mackall , Sadhna Shankar , Jim Vasselli , Francine Chen , Deryk Loo , Paul A. Moore , Jon M. Wigginton , Paul M. Sondel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics

Track

Developmental Therapeutics and Translational Research

Sub Track

Antibodies

Clinical Trial Registration Number

NCT02982941

Citation

J Clin Oncol 35, 2017 (suppl; abstr TPS2596)

DOI

10.1200/JCO.2017.35.15_suppl.TPS2596

Abstract #

TPS2596

Poster Bd #

88a

Abstract Disclosures

Similar Posters

First Author: Sadhna Shankar

First Author: Leo Mascarenhas

First Author: Steven G. DuBois

Poster

2014 ASCO Annual Meeting

Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.

Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.

First Author: Holly Jane Meany